Eye Drop Articles & Analysis
17 news found
SAN DIEGO–(BUSINESS WIRE)–Today, MediPrint™ Ophthalmics, an emerging San Diego-based clinical stage eye care pharmaceutical company focused on helping protect sight, announces the acceptance and presentation of a poster highlighting its latest clinical results at the upcoming Global Specialty Lens Symposium (GSLS), a leading eye care conference. ...
Patient #1, who entered the trial with a higher level of cystine crystal accumulation in the eye, reported a two-point photophobia score improvement 24 months post gene therapy. Patients #2 and #3, who both entered the trial with relatively lower cystine crystal accumulation in the eye, reported stable photophobia scores, both at 12 months post gene therapy. ...
François Blondel: ‘We work in three specific areas: degradation of the cartilage and the synovial fluid of joints, in order to combat problems with arthritis; skin ageing, which can result in the appearance of wrinkles; drying of the ocular surface, which is commonly known as ‘dry eye syndrome’. To slow down the ageing of tissues in these three so-called ...
SAN DIEGO–(BUSINESS WIRE) (March 15th, 2022) –Today, MediPrint™ Ophthalmics, an emerging San Diego-based clinical stage eye care pharmaceutical company focused on enhancing vision for life, announces the initial closing of a Series A round that exceeded $2.5 million, including from existing investors. There will be a subsequent close of this round, in Q2 2022, when the round is ...
Traditionally, early intervention in glaucoma has been limited primarily to prescription eye drops, with surgery reserved for more severe cases. However, prescription medications are only effective if they are taken as prescribed, and compliance can be a major issue. ...
Once all travoprost is released, theiDose TRwas designed to be removed and replaced with a newiDose TR, thus potentially offering an alternative to daily eye drop treatment. The 154-subject, multi-center, randomized, double-blind Phase 2b trial was designed to evaluate a single administration of one of twoiDose TRmodels with different travoprost release rates ...
Present in the vast majority of DED cases, MGD is largely undertreated, with no insured treatment options currently available that can address MGD as the root cause of dry eye. Meibum, a clear, oily secretion that is expressed through the eye’s meibomian glands, works to coat the outermost layer of the eye and protect tears from premature ...
Today, MediPrint™ Ophthalmics, an emerging San Diego-based clinical stage eye care pharmaceutical company focused on helping protect sight, announces its new corporate branding and new website. The new corporate logo was designed to better reflect and illustrate the purpose and passion underlying the Company’s goal to use the MediPrint process to help protect sight by printing ...
Key learnings from the market study included an acknowledgment of the relative inadequacy of eye drops, today’s standard of care, because of low compliance, an almost universal desire to find better ways to treat patients and a high likelihood of prescribing MediPrint™ lenses for their patients when the lenses become available. ...
Today, MediPrint™ Ophthalmics, an emerging San Diego-based clinical stage eye care pharmaceutical company focused on helping protect sight, announces the successful completion of the first study in its SIGHT (Sustained Innovative Glaucoma and ocular Hypertension Treatment) clinical program aimed at treating mild to moderate glaucoma and ocular hypertension. SIGHT-1 ...
ADVANCEMENTS IN EYE CARE: FATHER-SON TEAM RESTORING SIGHT At the height of the pandemic, across most medical specialties, doctors noted a sharp drop in care as patients curbed nonessential visits and procedures out of the fear that a medical appointment could lead to the coronavirus infection. ...
The Latanoprost FA SR Ocular Implant is designed to substitute for daily drop therapy by providing sustained treatment from a single implant administration over a six-month period to treat glaucoma. Up to 46 percent of patients do not remember to use their eye drops or administer them poorly. Adherence to daily drop therapy is ...
SAN DIEGO, CA, USA (Business Wire August 5th, 2020) – Today, Leo Lens Pharma, an emerging San Diego-based pharmaceutical company focused on helping protect sight, announces the expansion of its Scientific Advisory Board (SAB) that now comprises seven world-class eye care professionals, including three ophthalmologists and four optometrists. Leo Lens expanded its SAB with four eye care ...
OcuRing is a novel drug delivery platform for cataract surgery with potential to eliminate the need for postoperative topical eye drops. $3M DoD award will fund IND-enabling toxicology and manufacturing activities. ...
LL-BMT1 is a therapeutic contact lens that delivers preservative-free bimatoprost to the eye to treat glaucoma for one week. After a productive Pre-IND meeting with the FDA, Leo Lens has now successfully completed GLP biocompatibility studies required by the FDA, secured a clinical research organization to oversee the initial human clinical trial, secured the clinical site, and ...
Current glaucoma treatment requires eye drops to be administered daily, often multiple times each day. Instead the revolutionary implant delivers the medication to the eye for at least 30-weeks without the patient needing to administer drops, and then biodegrades completely, leaving no residue. Compliance is a major problem ...
"Implantable extended release formulations are an emerging class of treatments for glaucoma. Conventional eye drops are often ineffective due to lack of patient compliance with their prescribed regimens," explains Dr. ...